Application of Cold Plasma Treatment for Antimicrobial Contact Lenses

Projektinformationen

MePlat

ID Finanzhilfevereinbarung: 761883

DOI 10.3030/761883

Abgeschlossenes Projekt

EK-Unterschriftsdatum 4 Februar 2017

Startdatum 1 März 2017

Enddatum 31 Juli 2017

Finanziert unter

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology

Gesamtkosten € 71 429,00

EU-Beitrag € 50 000,00

Koordiniert durch

MEDIPLASMA SRL
Italy

Ziel

While the market of contact lenses has evolved over the years, there still remains a need for contact lenses which inhibit or do not promote bacterial and microbial growth or adhesion to the surface of the lenses, while simultaneously being safe for the wearer.
Our company has identified a business opportunity based on cold plasma technology which will revolutionise the contact lens market.. We have the ability to modify the surface properties of the contact lens, to increase resistance to the attachment of bacteria, making the contact lens safer. Through our technology we will also increase the comfort of the contact lens by adding an aqueous layer which will reduce the chances of the lens drying out.
Based on successful clinical studies, the grafting of heparin to the surface of the contact lens, will decrease contact-lens-related morbidity. Heparin is a glycosaminoglycan and when exposed to a substrate (sulfur salt in our case), forms a molecular layer of water that prevents attachment of bacteria to the surface via adhesins . The possibility of grafting heparin directly to the surface of the contact lens will provide a much safer and more comfortable solution to contact lens users, one which lasts throughout the lifetime of the product.

With our process, we aim to disrupt the industry and drastically reduce incidents of severe eye infection resulting from inappropriate contact lens use and care. Furthermore, we aim to increase customer retention and reduce the dropout rate by making contact lenses more comfortable for the users, adding more relief and reducing instances of dryness and discomfort.
The project proposal MePlat was submitted in September 2016 and received a score of 13.71 surpassing all thresholds (4.62 Impact, 4.52 excellence, 4.57 Implementation). We strongly believe in the potential of our project and after studying closely the ESR and discussing the project with our contact point, we are hereby putting forward a revised resubmission.

Wissenschaftliches Gebiet

• engineering and technology › mechanical engineering › manufacturing engineering
• natural sciences › biological sciences › microbiology › bacteriology
• natural sciences › physical sciences › plasma physics
• social sciences › economics and business › business and management › business models
• engineering and technology › materials engineering › coating and films

Programm/Programme

• H2020-EU.2.1.4. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology Main Programme
• H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument

Thema/Themen

• SMEInst-03-2016-2017 - Dedicated support to biotechnology SMEs closing the gap from lab to market

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2016-2017

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-1-2016-2017

Finanzierungsplan

SME-1 - SME instrument phase 1

Koordinator

MEDIPLASMA SRL

• Netto-EU-Beitrag: € 50 000,00
• Adresse: Piazza Sannazaro 71 ; 80122 NAPLES ; Italien
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Sud › Campania › Napoli
• Region: Sud › Campania › Napoli
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 71 429,00